Journal of Pain and Palliative Care Pharmacotherapy, December 2018
The use of cannabis medications has grown in recent years for the symptomatic relief of chemotherapy-induced nausea/vomiting (CINV) and chronic pain (cancer-related and non-cancer-related). As states legalize the use of cannabis, it is important for pharmacists and other healt…
Archive for year: 2018
Molecular Aspects of Medicine, December 2018
Physical activity is an important lifestyle factor for growth, development, and sustained health throughout life. In recent years, the benefits of physical activity have drawn more attention to its physiological effects on the body, including well-being. The endocannabinoid sy…
Life Sciences, 15 November 2018
Cannabis sativa is one of the most popular recreational and medicinal plants. Benefits from use of cannabinoid agents in epilepsy, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and others have been suggested. It seems that the endocannabinoid system is also inv…
Phytotherapy Research, November 2018
Glioblastoma (GBM) is the most common and aggressive brain tumor, which causes the highest number of deaths worldwide. It is a highly vascularized tumor, infiltrative, and its tumorigenic capacity is exacerbated. All these hallmarks are therapeutic targets in GBM treatment, in…
Schizophrenia Bulletin, November 2018
Background: Cannabis use in young people is common and associated with psychiatric disorders. However, the prospective link between cannabis use and bipolar disorder symptoms has rarely been investigated. The study hypothesis was that adolescent cannabis use is associated with…
Biochemical Pharmacology, November 2018
Breast cancer is the second leading cause of death among women. Although early diagnosis and development of new treatments have improved their prognosis, many patients present innate or acquired resistance to current therapies. New therapeutic approaches are therefore warrante…
Psychopharmacology, November 2018
RATIONALE: Cannabidiol (CBD), a non-intoxicating component of cannabis, or the psychoactive Δ9-tetrahydrocannabiol (THC), shows anti-hyperalgesia and anti-inflammatory properties. OBJECTIVES: The present study evaluates the anti-inflammatory and anti-hyperalgesia effects of CB…
EPIDIOLEX®, a cannabidiol oral solution has been transferred to Schedule V, the lowest restriction classification, by the U.S. Drug Enforcement Administration. But CBD remains on Schedule I, due to its supposed abuse liability.
Dr. Ethan Russo’s research on the Grand Unified Theory (GUT) that discusses how cannabis-based treatment and nutritional approaches can address five conditions that are difficult to treat with conventional medicine.
In this seminal study, Dr. Dedi Meiri and his team from Israel enhance our knowledge of the content, effect, and variability of cannabinoids across 36 individual cannabis cultivars.
Annals of Palliative Medicine, October 2018
Pain and symptom control challenges are common in palliative care, and the search for other therapeutic strategies is ongoing. Unfortunately, patients and their caregivers are receiving little information or support from healthcare providers regarding the increasingly popular…
Frontiers in Immunology, 21 September 2018
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the experimental a…